Testing obinutuzumab as ongoing treatment for brain and spinal cord lymphoma
Official title: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
It tests a drug given after brain or spinal cord lymphoma responds to treatment.
Read our full plain-language summary
What the trial team says
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Key facts
- Registry number
- NCT06175000
- Stage of testing
- Phase 2
- Conditions studied
- Primary Central Nervous System Lymphoma
Where it is running
This trial lists 7 sites.
-
New York
- Memorial Sloan Kettering Cancer Center (New York)
-
Ohio
- Cleveland Clinic (Cleveland)
-
Oregon
- Providence Health & Services; Providence Neurological Specialties (Portland)
-
Pennsylvania
- Pennsylvania State University (Hershey)
-
Vermont
- University of Vermont (Burlington)
-
Virginia
- University of Virginia (Charlottesville)
-
Washington
- Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute (Seattle)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.